肺癌早期诊断
Search documents
【中国新闻网】助力肺癌早期诊断 中国研发全球首个肺结节辅助诊断试剂盒获批上市
Zhong Guo Xin Wen Wang· 2026-01-27 02:24
胡海研究员(中) 与团队成员交流。中国科学院杭州医学研究所 供图 一方面,早期肺癌多无症状,多数患者就诊时已属晚期;另一方面,肺部小结节大多为良性,让不 少人陷入"结节焦虑",甚至出现过度诊疗。如何破解肺癌早期诊断的这一困境广受关注。 人体生物系统极为复杂,要精准找到肺癌特异性标志物如同"大海捞针"。研发团队攻克多项技术难 关,利用百万级癌症组织文库和多模态高通量筛选技术,结合合成生物学方法,重组表达400余种肺癌 早期关键蛋白,最终通过自主开发的液态悬浮芯片技术和人工智能算法,筛选出13种诊断性能最优的标 志物组合,其中8种为全新发现的标志物,远超现有临床应用水平。 应用优势获多中心临床试验印证 为让实验室成果落地应用,研发团队还突破生产工艺瓶颈,通过定制化蛋白标签设计、优化缓冲液 配方等创新,并攻克检测干扰、批间差异大等问题。引入冻干工艺后,冷藏条件下,试剂盒产品货架期 延长至12个月,且所有核心原料均实现自主生产,保障了产能与稳定性。 聚焦这一痛点,他领导项目团队从2016年起锁定肿瘤自身抗体检测技术持续攻关研发,该技术能捕 捉早期肺癌的"分子信号",在癌细胞数量极少、病情隐匿时就能发出预警,非常适合早 ...
印度尼帕病毒疫情或来自医院;全国三级公立中医院实现儿科全覆盖【21健讯Daily】
2 1 Shi Ji Jing Ji Bao Dao· 2026-01-26 23:43
Policy Developments - The National Health Commission released the "Guidelines for Clinical Application of New Antitumor Drugs (2025 Edition)" to standardize the clinical use of new antitumor drugs, which include small molecule targeted drugs and monoclonal antibodies [2] Drug and Device Approvals - North China Pharmaceutical announced it received a drug registration certificate for Tacrolimus capsules (0.5mg, 1mg), which is an immunosuppressant used to prevent organ transplant rejection [4] - A new lung cancer early diagnosis kit developed by the Hangzhou Institute of Medicine has been approved for market release, potentially improving early diagnosis rates for lung cancer [5] Financial Reports - YaoXingTang projected a net profit of 260 million to 330 million yuan for 2025, representing a year-on-year increase of 127.79% to 189.12%, driven by improved operational efficiency and resource allocation [7] - MaiDe Medical expects a revenue of approximately 447 million yuan for 2025, marking a year-on-year increase of about 62.81%, and anticipates a net profit of around 66.52 million yuan, indicating a turnaround from previous losses [8] Capital Market Activities - Tongrentang Medical submitted an IPO application to the Hong Kong Stock Exchange, with CICC as the sponsor [10] - New Jingzhiyuan Biotech completed over 200 million yuan in Series B financing, led by Xingze Capital and a well-known industry fund [11] Industry Developments - Over 40% of county-level traditional Chinese medicine hospitals have initiated the establishment of county medical communities, with a total of 3,099 such communities formed across 2,199 counties and cities [13] - The National Health Commission reported that all tertiary public traditional Chinese medicine hospitals have achieved full coverage in pediatrics, enhancing health services for children and the elderly [14]